^
Association details:
| Biomarker: | NRAS Q61K |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + refametinib (BAY86-9766) (MEK inhibitor, ERK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
Excerpt:
Patients with RAS mutations appear to benefit from refametinib/sorafenib combination….Plasma from 69 patients was evaluated for the following mutations: KRAS (G12A, C, D, R, S, V; G13D; Q61H; A146T), NRAS (Q61H, K, L, R), and BRAF (V600E).
DOI:
10.1158/1078-0432.CCR-13-3445
